Advancing Disease Modeling for Drug Discovery by Modulating iPSCs with CRISPR and Neuronal Differentiation

Description

Explore applications of CRISPR and iPSCs in disease modeling and drug discovery in our upcoming webinar with Synthego and BrainXell.

Standardizing cell models is essential for drug discovery and investigating mechanisms influencing disease onset. Using iPSC-derived neurons and glia marks a revolutionary shift in drug discovery, enabling direct study of novel therapeutics on human neurons without relying on primary human tissue. By creating specific neuron and glia subtypes, researchers can delve into disease pathways, comparing edited to control cell lines to aid in developing therapeutics to treat those diseases.

To accelerate the drug discovery workflow focused on curing neurodegenerative and neuro-related diseases, Synthego and BrainXell’s partnership is streamlining this workflow by leveraging Synthego’s CRISPR expertise and BrainXell’s mastery of working with iPS cells and neurons to make curing those diseases within reach.